Nasdaq · Healthcare
Keros Therapeutics, Inc. (KROS)
As-reported financials and recent SEC filings for Keros Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$244.1M
Net income
$87.0M
Net margin
35.7%
Diluted EPS
$2.30
ROE
28.7%
P/E (TTM)
4.8×
Market cap
$217.5M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 | $20.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $67.6M | $-210.8M | $-169.9M | $-114.8M | $-56.4M |
| Net income | $87.0M | $-187.4M | $-153.0M | $-104.7M | $-58.7M |
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-25
View on EDGAR →42026-06-17
View on EDGAR →42026-06-15
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on KROS
Search Keros Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.